Johnson & Johnson (NYSE:JNJ) Shares Sold by Broderick Brian C

Broderick Brian C lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 78,306 shares of the company’s stock after selling 1,762 shares during the quarter. Johnson & Johnson comprises approximately 2.2% of Broderick Brian C’s holdings, making the stock its 21st largest position. Broderick Brian C’s holdings in Johnson & Johnson were worth $11,325,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Principal Financial Group Inc. increased its stake in shares of Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after acquiring an additional 329,473 shares during the period. United Bank boosted its stake in Johnson & Johnson by 5.6% during the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after purchasing an additional 202 shares in the last quarter. Resurgent Financial Advisors LLC increased its position in shares of Johnson & Johnson by 10.1% during the 3rd quarter. Resurgent Financial Advisors LLC now owns 13,297 shares of the company’s stock valued at $2,155,000 after purchasing an additional 1,217 shares during the period. Royal London Asset Management Ltd. raised its stake in shares of Johnson & Johnson by 2.0% in the 3rd quarter. Royal London Asset Management Ltd. now owns 1,626,795 shares of the company’s stock worth $263,638,000 after buying an additional 31,334 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its stake in Johnson & Johnson by 29.0% during the third quarter. Quantinno Capital Management LP now owns 219,599 shares of the company’s stock valued at $35,588,000 after buying an additional 49,307 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on JNJ shares. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday. Raymond James cut their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $159.90 on Friday. The firm has a 50 day simple moving average of $159.63 and a 200 day simple moving average of $156.01. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a market cap of $385.33 billion, a P/E ratio of 24.04, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the company posted $2.29 EPS. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.